ES2067457T3 - Celula de origen animal con una proteina antigenica introducida en ella. - Google Patents

Celula de origen animal con una proteina antigenica introducida en ella.

Info

Publication number
ES2067457T3
ES2067457T3 ES88109455T ES88109455T ES2067457T3 ES 2067457 T3 ES2067457 T3 ES 2067457T3 ES 88109455 T ES88109455 T ES 88109455T ES 88109455 T ES88109455 T ES 88109455T ES 2067457 T3 ES2067457 T3 ES 2067457T3
Authority
ES
Spain
Prior art keywords
cells
modified
animal origin
antigenic protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88109455T
Other languages
English (en)
Inventor
Yves C Nicolau
Garret M Ihler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hapgood CV
Original Assignee
Hapgood CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26748809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2067457(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hapgood CV filed Critical Hapgood CV
Application granted granted Critical
Publication of ES2067457T3 publication Critical patent/ES2067457T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G01N33/555—Red blood cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)

Abstract

ESTA INVENCION COMPRENDE CELULAS ANIMALES DERIVADAS, EN ESPECIAL ERITROCITOS QUE HAN SIDO MODIFICADAS ARTIFICIALMENTE PARA QUE INCORPOREN EN SUS MEMBRANAS PLASMATICAS UN ANTIGENO, LA PROTEINA CD4 DERIVADA DE LINFOCITOS, LOQUE HACE QUE DE SEPAREN SELECTIVAMENTE Y SE CONDENSEN CON OTRAS CELULAS INFESTADAS CON UN VIRUS, ESPECIALMENTE VIRUS DE SIDA. ESTAS CELULAS MODIFICADAS PUEDEN SER ALTERADAS POSTERIORMENTE PATA QUE CONTENGAN EN SU CITOPLASMA UN AGENTE CITOTOXICO EN CUAL DESPUES DE QUE LA CELULA SE FUNDE CON UNA CELULA DIANA DARA LUGAR A LA MUERTE DE AMBAS CELULAS, CON LA SUBSIGUIENTE SEPARACION DEL SISTEMA RETICULOENDOTELIAL. TAMBIEN SE INCLUYE LA PRODUCCION Y EMPLEO DE LIPOSOMAS MODIFICADOS SIMILARMENTE. LA INVENCION PUEDE USARSE PARA EL TRATATAMIENTO DEL SIDA Y OTRAS ENFERMEDADES VIRICAS.
ES88109455T 1987-06-30 1988-06-14 Celula de origen animal con una proteina antigenica introducida en ella. Expired - Lifetime ES2067457T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6828887A 1987-06-30 1987-06-30
US19744588A 1988-05-27 1988-05-27

Publications (1)

Publication Number Publication Date
ES2067457T3 true ES2067457T3 (es) 1995-04-01

Family

ID=26748809

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88109455T Expired - Lifetime ES2067457T3 (es) 1987-06-30 1988-06-14 Celula de origen animal con una proteina antigenica introducida en ella.

Country Status (9)

Country Link
US (1) US5677176A (es)
EP (1) EP0298280B1 (es)
JP (2) JP2728166B2 (es)
AT (1) ATE114476T1 (es)
AU (2) AU1821988A (es)
CA (1) CA1327332C (es)
DE (1) DE3852221T2 (es)
ES (1) ES2067457T3 (es)
IL (1) IL86650A0 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
CA1327174C (en) * 1988-10-05 1994-02-22 Youssef Mouneimne Electro-insertion of proteins into animal cell membranes
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes
WO1990006960A1 (en) * 1988-12-22 1990-06-28 The Dow Chemical Company Improved process for synthesis of heterocyclic polymers
EP0555333B1 (en) * 1990-10-19 1995-12-27 University Of Florida Artificial viral envelopes
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
US5753258A (en) * 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
ATE157879T1 (de) * 1991-06-14 1997-09-15 Europ Communities Transformierte erythrozyten, verfahren zu deren herstellung, und ihre verwendung in pharmazeutischen zusammensetzungen
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
EP0630407B1 (en) * 1992-03-11 2000-08-02 PRENDERGAST, Kenneth, Francis Anti-viral fusion peptides
WO1994004677A1 (en) * 1992-08-13 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of cd4 plasma membrane vesicles (pmv) as a therapeutic agent for aids
CA2144767A1 (en) * 1992-09-22 1994-03-31 Guerard W. Byrne Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
HUT76331A (en) * 1994-07-15 1997-08-28 Lepetit Spa Dinucleoside-5',5'-pyrophosphates
US5591448A (en) * 1994-11-21 1997-01-07 Tepic; Slobodan Anti-viral therapeutic composition
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
WO2000029556A2 (en) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of glycosphingolipids that promote hiv-1 entry into cells
PL193824B1 (pl) 1998-12-23 2007-03-30 Idea Ag Preparat zawierający środki penetrujące, sposób wytwarzania preparatu zawierającego środki penetrujące oraz zastosowanie preparatu do wytwarzania leku
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
EP1921451A3 (en) * 2001-05-22 2008-05-28 Cygene, Inc. Complement mediated assays for in vivo and in vitro methods
AU2002343279B2 (en) 2001-10-16 2008-09-25 Kode Biotech Limited Sensitivity controls for blood serology prepared from modified cells
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CN102046151A (zh) * 2008-03-26 2011-05-04 牛津大学 靶向内质网的脂质体
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
EP2485983B1 (en) * 2009-10-08 2017-05-03 Otsuka Pharmaceutical Co., Ltd. An immunoactivation blood perfusion filter for the treatment of malignant tumors
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
AU2015241422B2 (en) 2014-04-01 2020-12-03 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
FR2564319A1 (fr) * 1984-05-21 1985-11-22 Inst Nat Sante Rech Med Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes

Also Published As

Publication number Publication date
CA1327332C (en) 1994-03-01
US5677176A (en) 1997-10-14
AU662154B2 (en) 1995-08-24
EP0298280A2 (en) 1989-01-11
IL86650A0 (en) 1988-11-30
JPH1072368A (ja) 1998-03-17
JP2825804B2 (ja) 1998-11-18
EP0298280A3 (en) 1990-05-02
AU1821988A (en) 1989-04-27
EP0298280B1 (en) 1994-11-30
JP2728166B2 (ja) 1998-03-18
ATE114476T1 (de) 1994-12-15
DE3852221D1 (de) 1995-01-12
AU1942692A (en) 1992-09-24
DE3852221T2 (de) 1995-04-06
JPH01124382A (ja) 1989-05-17

Similar Documents

Publication Publication Date Title
ES2067457T3 (es) Celula de origen animal con una proteina antigenica introducida en ella.
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
ES8503951A1 (es) Un procedimiento para preparar un complejo inmunogenico que contiene proteinas o peptidos antigenicos
MX9203439A (es) Una citocina mamifera, il-11
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
AU7489687A (en) Translation of mrna
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
NO912825L (no) Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.
HUP0000318A2 (hu) Tumorvakcina és eljárás előállítására
DE58909850D1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
IT1254360B (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
NL7901241A (nl) Nieuwe gesubstitueerde 2-fenylimino-imidazolidinen, de zuuradditiezouten daarvan, farmaceutische preparaten die deze bevatten, alsmede werkwijze voor de bereiding daarvan.
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
FI890603A (fi) Menetelmä HIV-hiukkasimmunogeenin ja sen vasta-aineen valmistamiseksi
NO179855C (no) Fremgangsmåte for fremstilling av et legemiddel
ES2061731T3 (es) Procedimiento de extraccion de antigenos de membrana con propiedades inmunogenicas de celulas neoplasicas humanas y los productos asi obtenidos.
GB1114683A (en) Process for purifying proteinaceous fractions from mistletoe by ultracentrifugation
Van Den Heuvel et al. Isolation of a bovine plasma fibronectin-containing complex which inhibits the expression of bovine leukemia virus p24
Powell et al. Identification of SIV/SMM viral proteins that induce T cell response in experimentally infected rhesus macaques and naturally infected sooty mangabeys by the cellular western blot assay
ES2011679A6 (es) Procedimiento para la preparacion de polipeptidos sinteticos secuenc iales inmunologicamente activos.
IT8321829A0 (it) Processo per la preparazione di concentrati di albumina aventi una consistenza da solida fino a quella di gel a partire da sangue e/o da plasma sanguigno di animali.
Khabas et al. An investigation of purified tetanus toxoid by the method of precipitation in agar
DK302987A (da) Fremgangsmaade til fremstilling af et immunogent kompleks
IT8421612A0 (it) Vettore clonante, procedimento per la sua costruzione e procedimentodi concentrazione e di purificazione di proteine prodotte, formate dal vettore clonante.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 298280

Country of ref document: ES